Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies
Maria Teresa Cencioni, Miriam Mattoscio, Roberta Magliozzi, et al.
Nature Reviews Neurology (2021) Vol. 17, Iss. 7, pp. 399-414
Closed Access | Times Cited: 176

Showing 1-25 of 176 citing articles:

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM
Tobias V. Lanz, R. Camille Brewer, Peggy P. Ho, et al.
Nature (2022) Vol. 603, Iss. 7900, pp. 321-327
Open Access | Times Cited: 590
Epstein–Barr virus and multiple sclerosis
Samantha S. Soldan, Paul M. Lieberman
Nature Reviews Microbiology (2022) Vol. 21, Iss. 1, pp. 51-64
Open Access | Times Cited: 296
The immunology of multiple sclerosis
Kathrine E. Attfield, Lise T. Jensen, Max Kaufmann, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 12, pp. 734-750
Closed Access | Times Cited: 220
Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade
George Crișan, Nastasia Sanda Moldovean-Cioroianu, Diana-Gabriela Timaru, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 5023-5023
Open Access | Times Cited: 181
The neuroimmune axis of Alzheimer’s disease
Mehdi Jorfi, Anna Maaser-Hecker, Rudolph E. Tanzi
Genome Medicine (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 169
Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications
Kjetil Bjørnevik, Christian Münz, Jeffrey I. Cohen, et al.
Nature Reviews Neurology (2023)
Closed Access | Times Cited: 130
Multiple sclerosis: Neuroimmune crosstalk and therapeutic targeting
Marc Charabati, Michael A. Wheeler, Howard L. Weiner, et al.
Cell (2023) Vol. 186, Iss. 7, pp. 1309-1327
Open Access | Times Cited: 119
Bruton tyrosine kinase inhibitors for multiple sclerosis
Julia Krämer, Amit Bar‐Or, Timothy J. Turner, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 5, pp. 289-304
Open Access | Times Cited: 99
Therapeutic Advances in Multiple Sclerosis
Jennifer H. Yang, Torge Rempe, Natalie Whitmire, et al.
Frontiers in Neurology (2022) Vol. 13
Open Access | Times Cited: 89
Advances in Neurodegenerative Diseases
Jeroen Van Schependom, Miguel D’haeseleer
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1709-1709
Open Access | Times Cited: 80
Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target
Rongzeng Liu, Shushu Du, Lili Zhao, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 79
Epstein-Barr virus as a cause of multiple sclerosis: opportunities for prevention and therapy
Francesca Aloisi, Gavin Giovannoni, Marco Salvetti
The Lancet Neurology (2023) Vol. 22, Iss. 4, pp. 338-349
Closed Access | Times Cited: 72
Revolutionizing anti-tumor therapy: unleashing the potential of B cell-derived exosomes
Jingwen Xiong, Hao Chi, Guanhu Yang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 52
B cell depletion therapy does not resolve chronic active multiple sclerosis lesions
Pietro Maggi, Colin Vanden Bulcke, Edoardo Pedrini, et al.
EBioMedicine (2023) Vol. 94, pp. 104701-104701
Open Access | Times Cited: 45
Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis
Julia Åkesson, Sara Hojjati, Sandra Hellberg, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 41
Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis
Massimiliano Calabrese, Paolo Preziosa, Antonio Scalfari, et al.
Annals of Neurology (2024) Vol. 96, Iss. 1, pp. 1-20
Open Access | Times Cited: 28
B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases
Aiden Haghikia, Georg Schett, Dimitrios Mougiakakos
The Lancet Neurology (2024) Vol. 23, Iss. 6, pp. 615-624
Open Access | Times Cited: 21
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Monica Margoni, Paolo Preziosa, Massimo Filippi, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1316-1334
Open Access | Times Cited: 85
Early developing B cells undergo negative selection by central nervous system-specific antigens in the meninges
Yan Wang, Dianyu Chen, Di Xu, et al.
Immunity (2021) Vol. 54, Iss. 12, pp. 2784-2794.e6
Open Access | Times Cited: 84
Immune Reconstitution Following Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: A Review on Behalf of the EBMT Autoimmune Diseases Working Party
Maria Teresa Cencioni, Angela Genchi, Gavin Brittain, et al.
Frontiers in Immunology (2022) Vol. 12
Open Access | Times Cited: 48
Cladribine Tablets for Relapsing–Remitting Multiple Sclerosis: A Clinician’s Review
Gavin Giovannoni, Joela Mathews
Neurology and Therapy (2022) Vol. 11, Iss. 2, pp. 571-595
Open Access | Times Cited: 42
Molecular Mechanisms of Immunosenescene and Inflammaging: Relevance to the Immunopathogenesis and Treatment of Multiple Sclerosis
Océane Perdaens, Vincent Van Pesch
Frontiers in Neurology (2022) Vol. 12
Open Access | Times Cited: 39
Potential biological contributers to the sex difference in multiple sclerosis progression
Nuria Álvarez‐Sánchez, Shannon E. Dunn
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 30
Proteogenomic links to human metabolic diseases
Mine Koprulu, Julia Carrasco-Zanini, Eleanor Wheeler, et al.
Nature Metabolism (2023) Vol. 5, Iss. 3, pp. 516-528
Open Access | Times Cited: 26
Personalized Use of Disease-Modifying Therapies in Multiple Sclerosis
Chi‐Yan Lee, Koon‐Ho Chan
Pharmaceutics (2024) Vol. 16, Iss. 1, pp. 120-120
Open Access | Times Cited: 15
Page 1 - Next Page

Scroll to top